Viking Therapeutics to Conduct Four Phase 3 Clinical Trials for Obesity Treatment VK2735
VKTX Viking Therapeutics Inc
$26.88 +0.30%
View chart & analysis → - 1Viking Therapeutics is conducting four Phase 3 obesity clinical trials for VK2735.
- 2Viking Therapeutics raised net proceeds of $547.8 million through stock issuance and convertible notes.
- 3A recent small-scale 33-week maintenance study exploratory cohort recorded a 21.7% weight reduction after 33 weeks.
So what's the key point?
Viking Therapeutics has started obesity treatment trials in four locations. It is important that results showed a 21.7% weight reduction over 33 weeks.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.